Last reviewed · How we verify

magnesium sulphate& levobupivacaine

South Egypt Cancer Institute · Phase 3 active Small molecule

Magnesium sulphate acts as a calcium channel blocker, while levobupivacaine is a local anesthetic that blocks sodium channels.

Magnesium sulphate acts as a calcium channel blocker, while levobupivacaine is a local anesthetic that blocks sodium channels. Used for General anesthesia, Spinal anesthesia.

At a glance

Generic namemagnesium sulphate& levobupivacaine
SponsorSouth Egypt Cancer Institute
Drug classCalcium channel blocker, Local anesthetic
TargetCalcium channels, Sodium channels
ModalitySmall molecule
Therapeutic areaAnesthesiology
PhasePhase 3

Mechanism of action

Magnesium sulphate's calcium channel blocking action helps to reduce muscle spasms and prevent seizures, while levobupivacaine's sodium channel blocking action numbs the area by preventing nerve impulses.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: